Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

169
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
169
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

286
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
286
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

508
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
508
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

369
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
369
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

168
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
168
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

385
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
385

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Socioeconomic status and epilepsy surgery in the United States: Timing and outcomes.

Epilepsia·2026
Same author

Association of antiseizure medication with lower amyloid and tau burden.

medRxiv : the preprint server for health sciences·2026
Same author

Global Socioeconomic Context and Brain Ageing in Epilepsy: an ENIGMA-Epilepsy study.

medRxiv : the preprint server for health sciences·2026
Same author

Agree to Disagree: Reliability of Seizure Frequency Assessments.

Epilepsy currents·2026
Same author

Moving artificial intelligence from research to real-world clinical use in neurology.

Nature reviews. Neurology·2026
Same author

Sex-related structural alterations across common epilepsies: a worldwide ENIGMA study.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jun 23, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.0K

Exit Strategy: Balancing the Risks and Rewards of Antiseizure Medication Withdrawal.

Marian Galovic1, Carolina Ferreira-Atuesta2, Lara E Jehi3

  • 1Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.

Epilepsy Currents
|June 20, 2024
PubMed
Summary

Most people with epilepsy can stop anti-seizure medications (ASMs) safely after achieving seizure freedom. This review offers evidence-based guidance on ASM withdrawal, considering surgery and acute seizures, to help manage risks and benefits.

Keywords:
acute symptomatic seizureantiseizure medicationdeprescribingepilepsyprognostic modelseizureseizure-freesurgerywithdrawal

More Related Videos

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery
10:46

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery

Published on: September 1, 2023

2.9K
Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
04:51

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy

Published on: April 11, 2019

9.4K

Related Experiment Videos

Last Updated: Jun 23, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.0K
Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery
10:46

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery

Published on: September 1, 2023

2.9K
Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
04:51

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy

Published on: April 11, 2019

9.4K

Area of Science:

  • Neurology
  • Pharmacology
  • Evidence-based Medicine

Background:

  • Epilepsy management often involves long-term anti-seizure medication (ASM) use.
  • Achieving seizure freedom opens possibilities for medication withdrawal, offering potential benefits but carrying risks.
  • Current literature requires critical examination to guide safe and effective ASM deprescribing.

Purpose of the Study:

  • To review evidence-based strategies for anti-seizure medication (ASM) withdrawal.
  • To explore prognostic models that inform deprescribing decisions in various epilepsy scenarios.
  • To emphasize shared decision-making in managing ASM withdrawal.

Main Methods:

  • Systematic review of existing literature on ASM withdrawal.
  • Analysis of deprescribing strategies for seizure-free individuals, post-surgery patients, and those with acute symptomatic seizures.
  • Evaluation of prognostic models for predicting withdrawal outcomes.

Main Results:

  • ASM withdrawal can offer significant benefits when seizure freedom is achieved.
  • Prognostic models show promise in guiding the decision-making process for ASM withdrawal.
  • Collaborative decision-making involving patients, caregivers, and physicians is crucial.

Conclusions:

  • Evidence-based recommendations for ASM withdrawal are essential for optimizing patient care.
  • Shared decision-making effectively manages the trade-offs associated with discontinuing ASMs.
  • Further research into prognostic models can enhance the safety and efficacy of epilepsy treatment discontinuation.